Lithium Clinics in Berlin and Dresden: a 50-Year Experience

2018 ◽  
Vol 51 (05) ◽  
pp. 166-171 ◽  
Author(s):  
Werner Felber ◽  
Michael Bauer ◽  
Ute Lewitzka ◽  
Bruno Müller-Oerlinghausen
Keyword(s):  
Side Effects ◽  
Lithium Treatment ◽  
Scientific Evidence ◽  
Bipolar Disorders ◽  
Lithium Therapy ◽  
Psychopharmacological Treatment ◽  
Academic Settings ◽  
History Of ◽  
The 1960S

AbstractAlthough lithium’s serendipitous discovery as a medication for depression dates back more than 200 years, the first scientific evidence that it prevents mania and depression arose only in the 1960s. However, at that time there was a lack of knowledge about how to administer and monitor lithium therapy safely and properly. The lithium clinics in Dresden and Berlin were remarkably similar in their beginnings in the late 1960s regarding patient numbers and scientific expertise without being aware of one another due to the Iron Curtain separating Germany into a western and eastern part until 1990. In what were initially lithium-care programs run independently from one another, the lithium clinics embedded in academic settings in Dresden and Berlin represent a milestone in the history of psychopharmacological treatment of affective disorders in Germany and trailblazers for today’s lithium therapy. Nowadays, lithium’s clinical applications are unquestioned, such as its use in strategies to prevent mood episodes and suicide, and to treat depression. The extensively documented knowledge of lithium treatment is the fruit of more than 50 years of observing disease courses and of studying side effects and influencing factors of lithium prophylaxis. Its safe and proper administration—in determining the correct indication, baseline and follow-up examinations, recommended dosages, monitoring, or the management of side effects—is well established. Subsequently, both national and international guidelines continue recommending lithium as the gold standard in treating patients with unipolar and bipolar disorders.

Treatment of varicose tributaries with sclerotherapy with polidocanol 0.5 % foam

VASA ◽  
2010 ◽  
Vol 39 (2) ◽  
pp. 169-174 ◽  
Author(s):  
Reich-Schupke ◽  
Weyer ◽  
Altmeyer ◽  
Stücker
Keyword(s):  
Scientific Evidence ◽  
Daily Practice ◽  
Severe Adverse Effect ◽  
Safe Procedure ◽  
Efficacy And Safety ◽  
Foam Sclerotherapy ◽  
History Of ◽  
One Year ◽  
Additional Therapy

Background: Although foam sclerotherapy of varicose tributaries is common in daily practice, scientific evidence for the optimal sclerosant-concentration and session-frequency is still low. This study aimed to increase the knowledge on foam sclerotherapy of varicose tributaries and to evaluate the efficacy and safety of foam sclerotherapy with 0.5 % polidocanol in tributaries with 3-6 mm in diameter. Patients and methods: Analysis of 110 legs in 76 patients. Injections were given every second or third day. A maximum of 1 injection / leg and a volume of 2ml / injection were administered per session. Controls were performed approximately 6 months and 12 months after the start of therapy. Results: 110 legs (CEAP C2-C4) were followed up for a period of 14.2 ± 4.2 months. Reflux was eliminated after 3.4 ± 2.7 injections per leg. Insufficient tributaries were detected in 23.2 % after 6.2 ± 0.9 months and in 48.2 % after 14.2 ± 4.2 months, respectively. Only 30.9 % (34 / 110) of the legs required additional therapy. In 6.4 % vein surgery was performed, in 24.5 % similar sclerotherapy was repeated. Significantly fewer sclerotherapy-sessions were required compared to the initial treatment (mean: 2.3 ± 1.4, p = 0.0054). During the whole study period thrombophlebitis (8.2 %), hyperpigmentation (14.5 %), induration in the treated region (9.1 %), pain in the treated leg (7.3 %) and migraine (0.9 %) occurred. One patient with a history of thrombosis developed thrombosis of a muscle vein (0.9 %). After one year there were just hyperpigmentation (8.2 %) and induration (1.8 %) left. No severe adverse effect occurred. Conclusions: Foam sclerotherapy with injections of 0.5 % polidocanol every 2nd or 3rd day, is a safe procedure for varicose tributaries. The evaluation of efficacy is difficult, as it can hardly be said whether the detected tributaries in the controls are recurrent veins or have recently developed in the follow-up period. The low number of retreated legs indicates a high efficacy and satisfaction of the patients.

Adenoid cystic carcinoma of the labium oris with rare metastasis to the pleural cavity

2021 ◽  
Vol 14 (1) ◽  
pp. e237622
Author(s):  
Osama Mosalem ◽  
Anas Alsara ◽  
Fawzi Abu Rous ◽  
Borys Hrinczenko
Keyword(s):  
Side Effects ◽  
Adenoid Cystic Carcinoma ◽  
Pleural Cavity ◽  
Epigastric Pain ◽  
Asian Woman ◽  
Upper Lip ◽  
Adenoid Cystic ◽  
History Of ◽  
The Right

A 57-year-old Southeast Asian woman with a remote history of adenoid cystic carcinoma (ACC) of the right labium superius oris (upper lip) presented to the hospital with vague epigastric pain. On workup, she was found to have multiple pleural nodules. Histopathology confirmed the diagnosis of metastatic ACC. After 8 months of active surveillance, evidence of disease progression was found and the patient was started on pembrolizumab. Follow-up after starting pembrolizumab showed stable disease with no significant side effects.

Recommendations for Monitoring Lithium Therapy

1983 ◽  
Vol 17 (5) ◽  
pp. 346-350 ◽  
Author(s):  
Ronald B. Salem
Keyword(s):  
Side Effects ◽  
Adverse Effects ◽  
Serum Levels ◽  
Normal Serum ◽  
Lithium Therapy ◽  
Organ Systems

The literature concerning side effects of normal serum levels of lithium on various organ systems is reviewed. Suggestions for monitoring and managing these adverse effects are discussed. A table is presented that provides recommendations for evaluation prior to initiation and during follow-up of therapy.

The Anthropocene Crisis

2016 ◽  
Vol 68 (4) ◽  
pp. 9 ◽  
Author(s):  
John Bellamy Foster
Keyword(s):  
Human Impacts ◽  
Scientific Evidence ◽  
Second World War ◽  
Fallout Radionuclides ◽  
Nuclear Weapons Testing ◽  
Silent Spring ◽  
History Of ◽  
The 1960S ◽  
Great Acceleration ◽  
Second World

The Anthropocene, viewed as a new geological epoch displacing the Holocene epoch of the last 10,000 to 12,000 years, represents what has been called an "anthropogenic rift" in the history of the planet.… Recent scientific evidence suggests that the period from around 1950 on exhibits a major spike, marking a Great Acceleration in human impacts on the environment, with the most dramatic stratigraphic trace of the anthropogenic rift to be found in fallout radionuclides from nuclear weapons testing.… Viewed in this way, the Anthropocene can be seen as corresponding roughly to the rise of the modern environmental movement, which had its beginnings in the protests led by scientists against above-ground nuclear testing after the Second World War, and was to emerge as a wider movement following the publication of Rachel Carson's Silent Spring in 1962. Carson's book was soon followed in the 1960s by the very first warnings, by Soviet and U.S. scientists, of accelerated and irreversible global warming. It is this dialectical interrelation between the acceleration into the Anthropocene and the acceleration of a radical environmentalist imperative in response that constitutes the central theme of Ian Angus's marvelous new book.Click here to purchase a PDF version of this article at the Monthly Review website.

Ibopamine Treatment in Chronic Hypotony Secondary to Long-Lasting Uveitis. A Case Report

2000 ◽  
Vol 10 (4) ◽  
pp. 332-334 ◽  
Author(s):  
P. Pivetti-Pezzi ◽  
S. Da Dalt ◽  
M. La Cava ◽  
M. Pinca ◽  
F. De Gregorio ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Intraocular Pressure ◽  
Case Report ◽  
Side Effects ◽  
Visual Field ◽  
Clinical Efficacy ◽  
Eye Drops ◽  
Days Of Therapy ◽  
History Of

Purpose To assess the clinical efficacy of ibopamine eye drops in severe hypotony secondary to chronic progressive uveitis. Methods Case report. A 47-year-old man with a 37-year history of diffuse uveitis and severe refractory hypotony was treated with topical 2% ibopamine (Trazyl®) six times a day. Intraocular pressure, visual acuity, visual field and side effects were recorded during 15 months of follow-up. Results IOP, visual acuity and visual field increased after four days of therapy and lasted for two months when the drug was suspended because of the onset of filamentous keratopathy. A new course of treatment with 2% ibopamine eye drops in a different solvent (BSS®) resulted in a stable increase in IOP, VA and visual field, with no side effects in a follow-up of 13 months. Conclusions Ibopamine 2% eye drops in BSS® solvent seem effective in the treatment of uveitis-related hypotony.

Ex juvantibus approach for chronic posterior laryngitis: results of short-term pantoprazole therapy

1999 ◽  
Vol 113 (8) ◽  
pp. 734-739 ◽  
Author(s):  
Walter Habermann ◽  
Andreas Eherer ◽  
Franz Lindbichler ◽  
Johann Raith ◽  
Gerhard Friedrich
Keyword(s):  
Side Effects ◽  
Proton Pump ◽  
Case History ◽  
Therapeutic Option ◽  
Short Term ◽  
Globus Pharyngeus ◽  
Symptom Questionnaire ◽  
History Of ◽  
Pharyngeal Reflux

AbstractThe aim of this study was to investigate whether patients with chronic posterior laryngitis and symptoms of gastro-pharyngeal reflux benefit from a six-week therapy with pantoprozole. Twenty-nine out-patients with voice disorders (case history of at least two months) and simultaneous symptoms of gastropharyngeal reflux were recruited for this study. At the entry to the study a symptom questionnaire and a videolaryngo/stroboscopy were completed. The symptom questionnaire and the video-laryngo/stroboscopy were repeated after the six weeks of therapy with pantoprazole 40 mg once a day and again six weeks and three months after this follow-up, during which time the patient was without therapy.Hoarseness, globus pharyngeus, sore throat, heartburn, and coughing were the symptoms which showed a significant (p<0.05) recovery at the follow-ups (mean of hoarseness index: 7.28 to 0.92; mean of globus pharyngeus index: 3.14 to 0.58; mean of heartburn index: 2.86 to 0.5; mean of cough index: 1.72 to 0.25; mean of throat soreness index: 1.72 to 0.15). Laryngoscopy scores of the posterior laryngeal region, the glottic and the supraglottic region showed statistically significant improvement (p<0.05) after the treatment with pantoprazole. The therapeutic effect exceeded the drug administration until the last follow-up (after three months). The medication was tolerated without side-effects in all patients.A primary (ex juvantibus) therapy with proton pump inhibitors seems to be a therapeutic option for patients with long-lasting chronic inflammation of the larynx not responding to common therapy. In this case a six-week course of treatment has been shown to be sufficient.

Unilateral immediate tonsillectomy as the treatment of peritonsillar abscess: Results, with special attention to pharyngitis

1983 ◽  
Vol 97 (12) ◽  
pp. 1105-1109 ◽  
Author(s):  
Per-Henrik Christensen ◽  
Ulf Schønsted-Madsen
Keyword(s):  
Side Effects ◽  
Previous History ◽  
Peritonsillar Abscess ◽  
Similar Group ◽  
Routine Treatment ◽  
History Of ◽  
Immediate Tonsillectomy

AbstractThe results of unilateral immediate tonsillectomy, as the routine treatment of peritonsillar abscess, were studies in 47 patients with no previous history of serious tonsillitis. The follow-up was carried out between three and four years after operation.The incidence of tonsillitis in the contralateral tonsil remained unchanged and peritonsillar abscess did not occur in that tonsil. Symptoms of pharyngitis, periodic or chronic, were present in three patients only. This was found to be significantly lower than that found in the literature in a similar group of patients in whom bilateral immediate tonsillectomy had been performed.The results are discussed and the authors recommend unilateral immediate tonsillectomy in cases of peritonsillar abscess in all patients with no previous history of serious tonsillitis, as this apparently prevents the troublesome side-effects of chronic pharyngitis.

scholarly journals Lithium in the treatment of bipolar disorder - monitoring of the adverse effects

2020 ◽  
Vol 73 (1-2) ◽  
pp. 49-53
Author(s):  
Milana Okanovic ◽  
Olga Zivanovic ◽  
Mina Cvjetkovic-Bosnjak ◽  
Vladimir Knezevic ◽  
Djendji Siladji ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Side Effects ◽  
Adverse Effects ◽  
Lithium Treatment ◽  
Lithium Therapy ◽  
Parathyroid Function ◽  
First Choice ◽  
Clinically Significant ◽  
American Academy Of Neurology

Introduction. Lithium therapy remains the gold standard in the treatment of bipolar disorder and clinical guidelines recommend it as the first choice for maintenance treatment of bipolar disorder. However, the use of lithium has decreased over the years, mainly due to the fear of its adverse effects. The aim of this paper was to review current literature data for the monitoring and overcoming side effects of lithium therapy in order to provide contemporary evidence for adequate lithium use. Material and Methods. A literature review of lithium therapy in bipolar disorder, using both Medline and manual searches, was performed. Classification of studies, in relation to their quality, was performed using the guidelines established by the American Academy of Neurology. Results. Despite methodological limitations of recent studies, there is irrefutable evidence that lithium therapy can cause toxicity and side effects related to renal, thyroid and parathyroid function, as well as weight gain. Conclusion. There is clear evidence that lithium can cause various side effects, but clinically significant conditions in this regard are rare and successfully treated. Literature data confirm strong efficacy of lithium and suggest its wider use in bipolar disorder. By following clinical recommendations and careful monitoring during lithium treatment, the risk of serious side effects is low compared to its efficacy.

scholarly journals Nonsurgical Method of Treatment of Childhood Phimosis with the use of Topical Betamethasone

1970 ◽  
Vol 8 (3) ◽  
pp. 176-180
Author(s):  
BK Rai
Keyword(s):  
Side Effects ◽  
Prospective Study ◽  
Past History ◽  
Topical Steroid ◽  
Effective Alternative ◽  
Surgical Method ◽  
History Of Disease ◽  
History Of ◽  
Systemic Side Effects

Background: Topical steroid application is an effective alternative to circumcision for the treatment of infant and childhood phimosis. Materials & method: prospective study in 42 boys under 13 years of age, with non retractable foreskin with asymptomatic and past history of disease in grade 4 to 6 weeks treatment. the success was defined as full and free retraction, or easy retraction limited only by congenital adhesions to the glans. Results: Forty-two patients completed the treatment. Successful retraction was achieved in 14 (33.33%) at 4 weeks and 32(76.19%) after 6 weeks of application. No adverse systemic side effects were noted. Two patients had failed treatment and were enrolled for circumcision. Two patients refused further treatment. Six patients were lost in subsequent to follow-up. Conclusion: Betamethasone 0.10% ointment is an effective alternative, non surgical method of the treatment for the childhood phimosis. Keywords: Chilhood phimosis; betamethasone DOI: 10.3126/hren.v8i3.4211Health Renaissance, September-December 2010; Vol 8 (No.3);176-180

The Evolution of Lithium Therapy

1992 ◽  
Vol 6 (2_suppl) ◽  
pp. 325-329 ◽  
Author(s):  
F. Neil Johnson
Keyword(s):  
Side Effects ◽  
Antidepressant Treatment ◽  
Lithium Treatment ◽  
Serum Levels ◽  
Clinical Applications ◽  
Lithium Therapy ◽  
Antidepressant Effect ◽  
Safe Medication ◽  
Recommended Treatment ◽  
Short Time

The evolution of lithium therapy for the treatment of mania and depression, from its discovery to the present day, is described. Early problems with toxicity have been overcome and lithium is now established as a safe medication, provided serum levels are monitored. The mechanism of action of lithium is not yet known, but biochemical models are beginning to be put forward. Lower doses of lithium than were previously used are now recommended. Treatment with intermittent doses of lithium (every second day) seems to reduce side effects, while maintaining clinical efficacy. Lithium has recently been used in combination with other medications. Augmentation of unsuccessful antidepressant treatment with lithium may produce an antidepressant effect within a short time. Withdrawal from lithium therapy usually results in a relapse. Lithium treatment is also used outside psychiatry. Other potential clinical applications for lithium therapy are discussed.

Sign in / Sign up

Export Citation Format

Share Document